Literature DB >> 2999006

Evidence for increased epidermal growth factor receptors in human sarcomas.

B Gusterson, G Cowley, J McIlhinney, B Ozanne, C Fisher, B Reeves.   

Abstract

The results of an immunocytochemical study of the epidermal growth factor receptor (EGFR) in 35 human soft-tissue sarcomas, using a murine monoclonal antibody (MAb) EGF-R1, are reported. In many of the tumours staining was stronger than in the adjacent stroma, suggesting increased levels of receptor. Particularly strong staining was seen in one epithelioid sarcoma and in the spindle-cell component of a synovial sarcoma. Binding studies carried out on an epithelioid sarcoma cell line established from one of the specimens, using radiolabelled EGF, showed that approximately 8% of the receptors were of high affinity with a dissociation constant (KD) of approximately 10(-10)M, while the remainder were of lower affinity with a KD of 10(-9)M. The cells expressed a total of 1.7 X 10(6) receptors/cell which is equivalent to that found in some epidermoid tumours where gene amplification has been demonstrated. These data suggest that, as with other tumours recently reported, increased levels of epidermal growth factor receptor may be related to transformation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999006     DOI: 10.1002/ijc.2910360612

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

1.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

2.  Expression of epidermal growth factor receptor in normal colorectal mucosa, adenoma, and carcinoma.

Authors:  K Koretz; P Schlag; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

3.  Renal cell cultures for the study of growth factor interactions underlying kidney organogenesis.

Authors:  L Mattii; F Bianchi; I Da Prato; A Dolfi; N Bernardini
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-04       Impact factor: 2.416

4.  Expression of epidermal growth factor receptor in benign and malignant primary tumours of the breast.

Authors:  P Möller; G Mechtersheimer; M Kaufmann; G Moldenhauer; F Momburg; T Mattfeldt; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

Review 5.  Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas.

Authors:  Blanca Homet Moreno; Elena Garralda Cabanas; Ricardo Hitt
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

6.  The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer.

Authors:  W Bergler; H Bier; U Ganzer
Journal:  Arch Otorhinolaryngol       Date:  1989

7.  Immunohistochemical distribution patterns of epidermal growth factor receptor in malignant mesothelioma and non-neoplastic mesothelium.

Authors:  M Ramael; K Segers; C Buysse; J Van den Bossche; E Van Marck
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

8.  Expression of epidermal growth factor receptors by odontogenic jaw cysts.

Authors:  T J Li; R M Browne; J B Matthews
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  Epidermal growth factor receptor expression in squamous cell lung carcinomas: an immunohistochemical and gene analysis in formalin-fixed, paraffin-embedded material.

Authors:  V Gorgoulis; A Giatromanolaki; A Karameris; C Tsatsanis; D Aninos; B Ozanne; M Veslemes; J Jordanoglou; R Trigidou; H Papastamatiou
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology.

Authors:  Torsten O Nielsen; Forrest D Hsu; John X O'Connell; C Blake Gilks; Poul H B Sorensen; Sabine Linn; Robert B West; Chih Long Liu; David Botstein; Patrick O Brown; Matt van de Rijn
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.